In 321 adults with moderate-to-severe active SLE (315 analysed), adding dapirolizumab pegol to standard care raised week-48 BICLA response vs placebo (50% vs 35%; difference 14·6, 95% CI 3·3–25·8). Adverse events 83% vs 75%; one death on dapirolizumab.
RCTn = 321
Clowse et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial